Figure 3.
Cost-effectiveness acceptability curve plot of the competing strategies. Across the tested willingness to pay range, the majority of trials found ERCP with FDA-recommended reprocessing to be the most cost-effective approach.
CBDE = common bile duct exploration; ERCP = endoscopic retrograde cholangiopancreatography; EtO = ethylene oxide; FDA = Food and Drug Administration; LC = laparoscopic cholecystectomy.